Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

SITC perspective: leveraging patient enrichment biomarkers to accelerate early phase IO drug development.

Journal for immunotherapy of cancer·2025

Same author

Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS).

Nature communications·2025

Same author

A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy.

Journal for immunotherapy of cancer·2025

Same author

A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancer.

Gynecologic oncology·2025

Same author

Spatial Architecture of Single-Cell and Vasculature in Tumor Microenvironment Predicts Clinical Outcomes in Triple-Negative Breast Cancer.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2024

Same author

Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockade.

Proceedings of the National Academy of Sciences of the United States of America·2024

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

GM-CSF-secreting vaccines for solid tumors.

Leisha A Emens¹

¹The Johns Hopkins University and Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, 1650 Orleans Street, Room 409, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231-1000, USA. emensle@jhmi.edu

Current Opinion in Investigational Drugs (London, England : 2000)

|November 28, 2009

Summary

Whole tumor cells secreting granulocyte-macrophage colony-stimulating factor (GM-CSF) show safety and activity. Further development of these cancer vaccines is recommended with combination therapies to enhance T-cell activation.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Related Experiment Videos

Last Updated: Jun 18, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Area of Science:

Immunology
Oncology
Vaccine Development

Background:

Whole tumor cells secreting granulocyte-macrophage colony-stimulating factor (GM-CSF) have shown early promise in clinical trials for cancer treatment.
Intradermal administration of these cells effectively recruits dendritic cells to present tumor antigens, activating CD4+ and CD8+ T-cells.

Purpose of the Study:

To evaluate the safety and clinical activity of GM-CSF-secreting whole tumor cell vaccines.
To identify strategies for further development and optimization of this cancer vaccine platform.

Main Methods:

Clinical trials involving intradermal administration of GM-CSF-secreting whole tumor cells.
Assessment of immune cell infiltration, antigen presentation, and T-cell activation.
Review of preclinical and clinical data to inform future trial design.

Main Results:

Demonstrated early evidence of safety and clinical activity in patients.
Observed massive infiltration of dendritic cells and activation of tumor-specific T-cells.
Identified trial design limitations that hindered Phase III evaluation.

Conclusions:

GM-CSF-secreting whole tumor cell vaccines represent a viable platform with demonstrated safety and immunomodulatory effects.
Future development should focus on combination therapies to overcome immune tolerance and enhance T-cell costimulation for improved vaccine efficacy.